[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362862-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362862-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","extrachromosomal-dna-drives-molecular-and-clinical-heterogeneity-in-hepatocellular-carcinoma-a-multi-omics-analysis-and-prognostic-model-development","Extrachromosomal DNA drives molecular and clinical heterogeneity in hepatocellular carcinoma - a multi-omics analysis and prognostic model development","","Extrachromosomal DNA (ecDNA) is investigated as an emerging cancer hallmark that may promote tumor evolution and heterogeneity, while its molecular features and clinical relevance in hepatocellular carcinoma (HCC) remain insufficiently defined. Clinical outcomes, genomics, transcriptomics, proteomics, tumor microenvironment, and drug target landscapes are compared between ecDNA-negative and ecDNA-positive cohorts from TCGA, and a LASSO/RSF approach selects an ecDNA gene signature. A nomogram integrates risk scores with clinicopathological variables and is supported by in vitro validation of DNASE1L3.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/extrachromosomal-dna-drives-molecular-and-clinical-heterogeneity-in-hepatocellular-carcinoma-a-multi-omics-analysis-and-prognostic-model-development/362862/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/extrachromosomal-dna-drives-molecular-and-clinical-heterogeneity-in-hepatocellular-carcinoma-a-multi-omics-analysis-and-prognostic-model-development/362862.png","ImageObject",300,407,{"name":42,"@type":43},"วิน","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical and molecular comparisons are made between ecDNA-positive and ecDNA-negative HCC?","Question",{"text":63,"@type":64},"The study compares clinical outcomes and multi-omics landscapes, including genomics, transcriptomics, proteomics, tumor microenvironment features, and drug target landscapes between ecDNA-positive and ecDNA-negative HCC using TCGA data.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is the ecDNA gene signature identified and turned into a prognostic tool?",{"text":68,"@type":64},"LASSO and random survival forest (RSF) algorithms screen the ecDNA gene signature, and a nomogram is constructed using the risk score together with clinicopathological features to evaluate prognosis.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genes are included in the validated prognostic signature and what biological role is tested experimentally?",{"text":72,"@type":64},"The validated six-gene signature includes RNF186, BMP6, AOC1, FBLL1, MYBL2, and DNASE1L3. DNASE1L3 is further validated through in vitro experiments to assess its effects on proliferation and migration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362862,1790171412,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Huang et al. Human Genomics (2026) 20:61 Human Genomics  \n[https://doi.org/10.1186/s40246-026-00927-w](https://doi.org/10.1186/s40246-026-00927-w)  \nRESEARCH Open Access  \nExtrachromosomal DNA drives molecular and clinical heterogeneity in hepatocellular carcinoma: a multi-omics analysis and prognostic model development  \nKai Huang1†, Guangquan Zhang1†, Shuai Hu1, Yongfei He1, Hang Zhai1, Junming Xu1, Jicai Wang1, Shengjie Hong1, Fenfang Wu1* and Xianjie Shi1*  \nAbstract  \nBackground Extrachromosomal DNA (ecDNA) is an emerging hallmark of cancer that promotes tumor evolution and heterogeneity. However, the molecular characteristics and clinical significance of ecDNA in hepatocellular carcinoma (HCC) remain incompletely understood.  \nMethods The clinical outcomes, genomics, transcriptomics, proteomics, tumor microenvironment, and drug target landscapes of ecDNA-negative and ecDNA-positive HCC in the Cancer Genome Atlas (TCGA) were compared. Next, the least absolute shrinkage and selection operator (LASSO) and random survival forest (RSF) algorithms were used to screen the ecDNA gene signature. A nomogram was constructed and evaluated based on the risk score and clinicopathological features. Finally, the role of DNASE1L3 was validated through in vitro experiments.  \nResults EcDNA-positive tumors showed increased vascular invasion, higher AFP levels, and moreTP53 mutations. These tumors displayed unique activation of proliferation pathways, decreased stromal infiltration, and heightened immune activation. Our validated six-gene signature (RNF186, BMP6, AOC1, FBLL1, MYBL2, and DNASE1L3) demonstrated strong prognostic value when combined with tumor stage in the nomogram. Notably, DNASE1L3 was downregulated in HCC, showed endothelial cell-specific expression, and suppressed the proliferation and migration of Hep3B2 .1-7 cells.  \nConclusion Our study characterizes the molecular and clinical distinctions between ecDNA-negative and ecDNApositive HCC and establishes a clinically applicable gene signature for patient prognosis. These findings advance our understanding of ecDNA-driven tumor heterogeneity and provide potential strategies for personalized HCC management.  \n†Kai Huang and Guangquan Zhang have contributed equally to this work.  \n*Correspondence: Fenfang Wu [wufenfang19@126.com](wufenfang19@126.com)[ ](wufenfang19@126.com)Xianjie Shi [shixj7@mail.sysu.edu.cn](shixj7@mail.sysu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nHuang et al. Human Genomics (2026) 20:61 Page 2 of 16  \nKeywords Hepatocellular carcinoma, Extrachromosomal DNA, Tumor microenvironment, Multi-omics analysis, Prognostic signature  \nIntroduction  \nLiver cancer ranks as the sixth most common cancer and the third leading cause of cancer-related deaths globally, with 865,000 new cases and 757,948 deaths","cbCair0PaVk1bvz9","https://ap.wps.com/l/cbCair0PaVk1bvz9","pdf",9951068,16,"English","# Abstract\n# Introduction\n## Background and clinical challenge in HCC\n## ecDNA as a driver of heterogeneity\n# Methods, results, and validation (study aims)","[{\"question\":\"What clinical and molecular comparisons are made between ecDNA-positive and ecDNA-negative HCC?\",\"answer\":\"The study compares clinical outcomes and multi-omics landscapes, including genomics, transcriptomics, proteomics, tumor microenvironment features, and drug target landscapes between ecDNA-positive and ecDNA-negative HCC using TCGA data.\"},{\"question\":\"How is the ecDNA gene signature identified and turned into a prognostic tool?\",\"answer\":\"LASSO and random survival forest (RSF) algorithms screen the ecDNA gene signature, and a nomogram is constructed using the risk score together with clinicopathological features to evaluate prognosis.\"},{\"question\":\"Which genes are included in the validated prognostic signature and what biological role is tested experimentally?\",\"answer\":\"The validated six-gene signature includes RNF186, BMP6, AOC1, FBLL1, MYBL2, and DNASE1L3. DNASE1L3 is further validated through in vitro experiments to assess its effects on proliferation and migration.\"}]","Extrachromosomal DNA drives molecular and clinical heterogeneity in hepatocellular carcinoma - a multi-omics analysis and prognostic model development | PDF",1790149260,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37009b61f2a515337ad6d2ddf021e679.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a502ba6906897e4c73271535a29f5fa4.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/265ba3991db20d20192600f17124fa7e.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51aa77709d15337b98b090ad1f92ccfa.webp",980,1306]